Chugai Pharmaceutical Co. Ltd (CHGCF PINK) stock market data APIs
$55.1233
0.15(0.3%)
as of November 19, 2025
Try our APIs with
free plan!
Chugai Pharmaceutical Co. Ltd Financial Data Overview
Price chart is built with
Anychart
Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. It offers oncology products, such as Alecensa, Avastin, FoundationOne, Herceptin, Kadcyla, Lunsumio, Perjeta, Polivy, Tecentriq, and Phesgo; Neutrogin and Sigmart; Actemra for humanized anti-human IL-6 receptor monoclonal antibody; CellCept for immunosuppressant; Edirol, an osteoporosis agent; Enspryng, a pH-dependent binding humanized anti-IL-6 receptor monoclonal antibody; Evrysdi for spinal muscular atrophy agent; Hemlibra, an anti-coagulation factor IXa/X humanized bispecific monoclonal antibody; Mircera, an erythropoiesis-stimulating agent; PiaSky, a pH-dependent binding humanized anti-complement (C5) monoclonal antibody; Ronapreve, an anti-SARS-CoV-2 monoclonal antibody; Tamiflu, an anti-influenza agent; and Vabysmo, an anti VEGF/anti Ang-2 bispecific antibody. The company has strategic alliances and collaboration with Roche Group; and research and license agreement with Gero PTE. LTD. to develop novel therapies for age-related diseases. The company was formerly known as Chugai Shinyaku Shokai and changed its name to Chugai Pharmaceutical Co., Ltd. in January 1943. The company was founded in 1925 and is headquartered in Chuo, Japan. Chugai Pharmaceutical Co., Ltd. operates as a subsidiary of Roche Holding Ltd.
Prev. Close
55.1233
Open
55.2759
High
55.5045
Low
53.5046
52 wk Range
31.2254-70.0029
Market Cap
95 709 M
P/E Ratio
35.4581
Shares Outstanding
1 646 M
Revenue
1 213 713 M
EPS
0.4582
Dividends (Yield)
0.0122
Beta
0.396
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Chugai Pharmaceutical Co. Ltd data using free add-ons & libraries
Get Chugai Pharmaceutical Co. Ltd Fundamental Data
Chugai Pharmaceutical Co. Ltd Fundamental data includes:
- Net Revenue: 1 213 713 M
- EBITDA: 579 513 M
- Earnings Per Share: 1
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-10-24
- EPS/Forecast: 73.28
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Chugai Pharmaceutical Co. Ltd News
New
Assessing Chugai Pharmaceutical (TSE:4519) Valuation Following Strong Share Price Gains
Chugai Pharmaceutical (TSE:4519) has delivered a steady annual revenue growth of nearly 5% and net income growth close to 9% recently. Investors keep a keen eye on these metrics as the healthcare land...
RANI: Third Quarter Results
By John Vandermosten, CFA NASDAQ:RANI READ THE FULL RANI RESEARCH REPORT On November 6th, Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) reported third quarter 2025 results. Since our last update f...
Rani Therapeutics Reports Third Quarter 2025 Financial Results; Provides Corporate Update
Rani Therapeutics, LLC – Announced up to $1.085 billion collaboration with Chugai Pharmaceutical Co. for multiple high-value therapeutics – – Completed $60.3 million oversubscribed private pla...
H.C. Wainwright Initiates Rani Therapeutics (RANI) with Buy and $11 PT on RaniPill Potential
Rani Therapeutics Holdings Inc. (NASDAQ:RANI) is one of the hot stocks to buy with huge upside potential. On October 21, H.C. Wainwright analyst Brandon Folkes assumed coverage of Rani Therapeutics wi...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
